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ABSTRACT
We previously identified the transcription factor ZNF217 (human) / Zfp217 
(mouse) as an oncogene and prognostic indicator of reduced survival, increased 
metastasis, and reduced response to therapy in breast cancer patients. Here we 
investigated the role of Zfp217 in chemotherapy resistance. Preclinical animal models 
of Zfp217 overexpression were treated with a combination therapy of the microtubule 
inhibitor epothilone B, doxorubicin (Adriamycin), and cyclophosphamide (EAC). Tumors 
overexpressing Zfp217 increased their tumor burden compared to control tumors after 
treatment and accumulated a mammary gland progenitor cell population (K8+K14+). 
To overcome this chemoresistance after ZNF217 overexpression, we treated tumors 
± Zfp217 overexpression with paclitaxel and triciribine, a nucleoside analog and AKT 
inhibitor that kills cells that overexpress ZNF217. Treatment order critically impacted 
the efficacy of the therapy. Combination treatment of triciribine followed by paclitaxel 
(TCN→PAC) inhibited tumor burden and increased survival in tumors that overexpressed 
Zfp217, whereas single agent or combination treatment in the reverse order (PAC→TCN) 
did not improve response. Analysis of these tumors and patient-derived tumor xenograft 
tumors treated with the same therapies suggested that Zfp217 overexpression in 
tumors contributes both to decreased microvessel density and vessel maturity, while 
TCN→PAC tumors overexpressing Zfp217 showed improved vessel maturity.
INTRODUCTION
Even if diagnosed with early stage disease, 
approximately one-third of breast cancer patients will 
have tumors that develop resistance to available therapies 
[1]. Unfortunately, the mechanisms used by cancer cells to 
develop resistance are not well understood, which leaves 
clinicians faced with decisions about the treatment options 
to use and the timing of these interventions. The survival 
of these patients requires identification of both novel 
predictive biomarkers and therapies used to overcome 
this resistance, particularly in life-threatening metastatic 
tumors. For this reason, it is beneficial to identify 
biomarkers that predict which breast cancer patients are 
at a higher risk of developing therapeutic resistance. 
Biomarkers can aid drug design, identify treatment 
regimens with increased efficacy, and prevent unnecessary 
treatment.
We previously identified ZNF217 (human)/Zfp217 
(mouse) as a candidate therapeutic target with prognostic 
value for resistance to breast cancer therapies [2, 3]. 
ZNF217 is a Krüppel-like zinc finger protein amplified and 
overexpressed in ~25% of breast cancer patients [4] and is 
a biomarker of poor prognosis [2]. Indeed, patients with 
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tumors that overexpress ZNF217 have reduced survival, 
increased metastasis, and increased chemoresistance. 
Zfp217 is oncogenic when overexpressed in mouse 
models of breast cancer, and this overexpression promotes 
chemoresistance [2, 5, 6]. ZNF217 overexpression also 
promotes paclitaxel and doxorubicin resistance in both cell-
based and xenograft models [2, 5, 6]. Recent in vitro studies 
also show that ZNF217 overexpression promotes tamoxifen 
resistance in mammary epithelial cells in culture [7].
Chemotherapy treatment of breast tumors leads to 
an increase in the percentage of stem/progenitor cells [8]. 
Stem/progenitor cells are candidate cells that are resistant to 
chemotherapy after ZNF217 overexpression. We previously 
found that Zfp217 overexpression promotes an increase in 
self-renewal capacity, invasion, and metastasis, as well as 
expansion of a progenitor cell population during both normal 
mammary development and breast cancer progression [2]. 
In addition, stem cells remain in chemoresistant tumors [8].
ZNF217 regulates the expression of ErbB3 [9] 
and promotes activation of Akt kinase activity [2]. Akt 
is a serine/threonine protein kinase involved in essential 
cellular processes including metabolism, cell growth, 
proliferation, cell cycle progression, and survival [10]. It 
has also been implicated in the pathogenesis of cancer with 
all three Akt family members having increased expression 
and activity in breast cancer [11].
Consistent with the AKT signaling pathway being 
a potential target after ZNF217 overexpression, our lab 
identified the Akt inhibitor triciribine as the only drug 
tested in vivo that has shown the potential to decrease 
tumor burden in a human breast xenograft with high 
ZNF217 expression [2, 12]. Several Akt inhibitors, 
including triciribine, have been and continue to be tested 
in clinical trials to treat solid tumors [13]. Triciribine has 
been explored as a treatment option in a phase II clinical 
trial for metastatic breast cancer [14].
Even though cell culture and patient data support 
a role for ZNF217 in chemoresistance, the equivalent in 
vivo experiments testing for chemoresistance in tumors 
that overexpress ZNF217 have not been completed. In 
this study, we first determine if Zfp217 overexpression 
in breast tumors promotes chemoresistance. We then 
investigate the efficacy of triciribine and paclitaxel 
combination therapy on these tumors. We also identify 
novel mechanisms of response to combined triciribine and 
paclitaxel treatment that will provide mechanistic insight 
into the increase in efficacy.
RESULTS
Increased expression of Zfp217 promotes 
chemoresistance in vivo
To determine experimentally if Zfp217 
overexpression in vivo caused chemotherapy resistance, 
we generated orthotopic transplants of mouse breast cancer 
cells ± Zfp217 in syngeneic hosts (Figure 1A). The breast 
cancer cells used were metastatic mammary epithelial cells 
derived from MMTV-PyMT [7] ±Zfp217 overexpression 
by lentiviral infection, as described [2, 15]. Once tumors 
formed in these animals, cohorts were treated with or 
without the following three chemotherapies: microtubule 
inhibitor epothilone B, doxorubicin (Adriamycin), and 
cyclophosphamide (EAC). Vector control mice treated 
with EAC had the greatest survival. Consistent with our 
previous study, vehicle-treated FVB mice with tumors 
overexpressing Zfp217 had a reduced median survival 
time of 8 days compared to 14 days for mice expressing 
vector. Vehicle treated mice with increased expression of 
Zfp217 also had larger tumor volumes compared to the 
EAC treated control cohort (Figure 1B) (p=0.0006, linear 
regression with slope comparison). These data suggest that 
tumors overexpressing Zfp217 develop resistance to the 
combination EAC chemotherapy.
Chemoresistant tumors that overexpress Zfp217 
have an expanded progenitor cell population 
(K8+/K14+)
To further study this Zfp217 driven chemoresistance, 
we examined the effects of EAC treatment on a K8+K14+ 
progenitor cell population. We previously found that 
Zfp217 overexpression promotes an increase in a 
progenitor cell population that expresses markers of 
luminal (keratin 8, K8) and myoepithelial (keratin 14, 
K14) cells (K8+K14+) during breast cancer progression 
[2]. These K8+K14+ double positive cells are a bipotent 
progenitor population capable of forming both luminal 
and myoepithelial cells [16–20]. We hypothesized that 
this K8+K14+ cell population might promote resistance to 
treatment by expanding a progenitor cell population.
We quantified the K8+K14+ population in the tumors 
generated ± Zfp217 overexpression and ± EAC treatment. 
Interestingly, the chemoresistant EAC treated tumors that 
overexpressed Zfp217 had significantly increased numbers 
of K8+K14+ cells (Figure 1D-1E). Overexpression of 
Zfp217 significantly increased the percentage of K8+K14+ 
cells in mice that received EAC chemotherapy when 
compared with the vehicle treated mice overexpressing 
Zfp217 (p=0.01) and with vector-expressing vehicle and 
EAC treated mice (p=0.001 and p=0.0001, respectively, 
one-way ANOVA with Tukey’s multiple comparisons) 
(Figure 1E). In contrast to our previously published 
results, overexpression of Zfp217 without treatment 
showed no significant difference in the K8+K14+ double 
positive cell population in vehicle treated mice. However, 
unlike the previous study, the samples in this experiment 
were collected only when the tumors reached a large size, 
rather than on the same day. Therefore, treated tumors that 
overexpress Zfp217 have increased numbers of K8+K14+ 
cells compared to vector, and this increase is unlikely 
due to differences in primary tumor burden and instead 
demonstrates that the K8+K14+ progenitor cell population 
is driven by overexpression of Zfp217.
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Figure 1: Increased expression of Zfp217 contributes to chemoresistance and an increase in a progenitor cell population. 
(A) Experimental overview of orthotopic transplants and combination therapy in orthotopic mammary transplants of Vo-PyMT-Luc 
cells that constitutively overexpress vector or Zfp217. Mice received a single treatment of epothilone B, doxorubicin (Adriamycin), and 
cyclophosphamide combination therapy. Tumor tissue was collected at death or at the terminal endpoint when the tumor diameter reached 
2.5 cm. (B) Kaplan-Meier survival curves of mice bearing orthotopic transplants of Vo-PyMT-Luc cells with constitutive overexpression of 
vector or Zfp217 after treatment with either EAC or vehicle. Kaplan-Meier survival curves show a significant decrease in median survival 
between vector and Zfp217 vehicle treated mice compared to mice that received EAC therapy (p=0.0003 and p=0.02 by log-rank test, 
respectively). The median survival significantly decreases after EAC therapy in mice overexpressing Zfp217 compared to vector (p=0.03 by 
log-rank test). (C) Tumor burden. Tumor volume was compared using linear regression analysis and the slopes of the lines were significantly 
different between vehicle and EAC treated vector and Zfp217 expressing tumors (p=0.0004 and p=0.0006, respectively). (D) K8+K14+ 
cells. Tumor sections from FVB mice ± Zfp217 ± EAC were stained for keratin-8 (K8+) and keratin-14 (K14+) by immunofluorescence 
staining of tumor sections. Arrowheads point to examples of K8+K14+ double positive cells. (E) Quantification of K8+K14+ cells. Bar graph 
showing results of number of K8+K14+ cells per field. There was a significant increase in the K8+K14+ double positive cells for Zfp217 
tumors treated with EAC compared to tumors expressing vector (p=0.01 by one-way ANOVA with Tukey’s multiple comparisons test). (F) 
Kaplan-Meier survival curves of mice bearing orthotopic transplants of Vo-PyMT-Luc cells with constitutive overexpression of vector or 
Zfp217 after treatment with EAC. Kaplan-Meier survival curves show a significant decrease in median survival between in Zfp217 + EAC 
treated mice compared to vector + EAC therapy (p=0.04 by log-rank test). The median survival significantly decreases after EAC therapy 
in mice overexpressing Zfp217 (26 days, median survival) compared to vector (35 days, median survival).
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We also examined the pathology of these tumors and 
found similar pathologies between the non-necrotic areas 
of the tumors (Supplementary Figure 1C).
Our data show that Zfp217 overexpression is 
sufficient to promote accelerated chemoresistance in vivo 
in breast tumors (Figure 1A-1C). Additionally, Zfp217 
induced chemoresistance supports the expansion of a 
K8+K14+ cell population (Figure 1D-1E).
We next repeated the experiment over a longer 
time course with more animals to analyze the survival 
after EAC treatment of animals with breast tumors that 
overexpress either vector or Zfp217 in a larger cohort 
(Figure 1F). Similar to our earlier experiment, Zfp217 
overexpressing tumors treated with EAC had reduced 
survival (26 days, median survival) compared to vector 
overexpressing tumors (35 days, median survival). These 
results confirm that Zfp217 overexpression accelerates 
chemoresistance by reducing the survival of these animals.
Increased expression of Zfp217 contributes to 
increased lung micrometastases
Increased detection of stem/progenitor cells is 
prognostic of increased metastasis in patients [21, 22]. 
After detecting the increase in number of K8+K14+ cells, 
we next examined lung metastasis in the same animals. 
Similar to our previous study, the percentage of mice 
that developed lung micrometastases was higher after 
overexpression of Zfp217 (Supplementary Figure 1A-
1B). In addition, chemotherapy treatment reduced but 
did not eliminate lung metastases compared to controls. 
Despite a small increase in the number of micrometastases 
in the cohort with tumors overexpressing Zfp217 and 
treated with vehicle, the quantity of micromets was not 
significantly different between the EAC treated cohorts 
(data not shown).
Dosing order determines tumor-free survival in 
Zfp217 induced model of chemoresistance
After establishing an in vivo model of Zfp217 
induced chemoresistance, we sought to identify a novel 
therapeutic regimen aimed at overcoming Zfp217-induced 
chemoresistance. We previously identified the nucleoside 
analog and Akt inhibitor triciribine as a therapeutic with 
potential to overcome Zfp217 induced chemoresistance 
[2]. Triciribine currently is in a Phase I-II clinical 
trial (NCT01697293) in which triciribine is used in 
combination with the microtubule inhibitor paclitaxel in 
patients with breast and other cancers. To overcome the 
Zfp217-induced tumor burden, we examined the efficacy 
of triciribine as a combination treatment with paclitaxel.
To model the design of the Phase II clinical 
trial (NCT01697293) and to determine if Zfp217 
overexpression is predictive of response to triciribine 
in breast cancer, we tested the efficacy of paclitaxel and 
triciribine as combination therapy in our preclinical animal 
models by transplantation of PyMT mammary cancer cells 
±Zfp217 overexpression. To determine if the order of drug 
treatment influenced the efficacy of the treatment, we 
varied the dosing order within our preclinical study. When 
tumors formed, we divided the mice into cohorts ±Zfp217 
and treated them with either vehicle, single agent, or 
combination therapies of either paclitaxel followed by 
triciribine treatment (PAC→TCN) or triciribine followed 
by paclitaxel treatment (TCN→PAC) for a short time 
course, at which point some animals began to die from 
large tumor burden (Figure 2A). We found that the median 
survival of 15 days and tumor burden from animals with 
tumors that overexpress vector did not significantly 
change after any of the treatment combinations [Kaplan-
Meier with log-rank (Mantel-Cox) test] (Figure 2B, 2D).
We next compared survival and tumor burden 
from animals with tumors that overexpress Zfp217 with 
single agent or combination therapy. Mice receiving the 
TCN→PAC treatment had the greatest survival (Figure 
2C). The mice with tumors overexpressing Zfp217 and 
treated with TCN→PAC developed significantly reduced 
tumor burden compared to animals treated with vehicle 
(p=0.001, linear regression with slope comparison) (Figure 
2E). Therefore, TCN→PAC combination therapy exhibits 
increased efficacy on tumors that overexpress Zfp217, but 
not vector. In addition, the treatment order matters and 
significantly influences the survival and tumor burden of 
mice with increased expression of Zfp217.
In summary, Zfp217 overexpression is predictive of 
response to triciribine and paclitaxel combination therapy. 
In addition, Zfp217-overexpressing tumors, but not vector-
expressing tumors, were responsive to triciribine when 
the mice were treated with triciribine prior to paclitaxel 
treatment, but not when the mice were treated with 
paclitaxel prior to triciribine treatment.
Tumors that overexpress Zfp217 and are treated 
with triciribine and paclitaxel have a reduced 
progenitor cell population (K8+/K14+)
We next examined the mechanisms behind the 
efficacy of the TCN→PAC treatment against tumors that 
overexpress Zfp217. Because we found the increase in 
number of K8+K14+ progenitor cells in resistant tumors 
that overexpress Zfp217, we reasoned that this population 
might be eliminated by treatment, which ultimately would 
reduce tumor burden if these K8+K14+ cells are the therapy-
resistant repopulating cells of the tumor. We quantified the 
K8+K14+ population of the TCN→PAC and PAC→TCN 
tumors (Figure 2F) and found that in mice with tumors 
overexpressing Zfp217, treatment with TCN→PAC 
reduced the number of K8+K14+ cells by 3-fold (p=0.03, 
one-way ANOVA with Tukey’s multiple comparisons).
We also examined the levels of proliferation and 
apoptosis in tumor tissues ± Zfp217 ± treatment by 
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Figure 2: Triciribine-paclitaxel (TCN→PAC) combination therapy increases survival and reduces tumor volume in 
immunocompetent mice with tumors that overexpress Zfp217. (A) Experimental overview. Vo-PyMT-Luc cells constitutively 
overexpressing vector or Zfp217 were orthotopically injected into recipient FVB mammary glands. Mice received weekly treatments 
of single or dual agent combination therapy. The dual agent regimen was administered with a delay of approximately 24 hours between 
delivery of the first and second drug. Tumor tissue was collected at death or at the terminal endpoint, when the tumor diameter reached 2.5 
cm. (B) Kaplan-Meier curves of recipient FVB mice bearing orthotopically grown Vo-PyMT-Luc cells expressing vector received single 
or dual agent combination therapy or vehicle. Kaplan-Meier survival curves show no change in median survival between cohorts. (C) 
Kaplan-Meier curves of FVB mice bearing orthotopically grown Vo-PyMT-Luc cells that are constitutively expressing Zfp217 received 
single or dual agent combination therapy or vehicle. Kaplan-Meier survival curves show a significant decrease in median survival between 
single agent paclitaxel and dual agent triciribine-paclitaxel compared to vehicle (p=0.0003 and p=0.02 by log-rank test, respectively). (D) 
Tumor burden in vector expressing glands after treatment. Tumor volume was compared using linear regression analysis and the slopes 
of the lines were not significantly different between vehicle and chemotherapy treated vector expressing tumors. (E) Tumor burden in 
Zfp217 overexpressing glands after treatment. Tumor volume was compared using linear regression analysis and the slopes of the lines 
were significantly different between vehicle and triciribine-paclitaxel treated Zfp217 expressing tumors (p=0.001). (F) Quantification 
of K8+K14+ cells. Bar graph showing results of number of K8+K14+ cells per field for dual agent treated cohorts expressing vector or 
Zfp217. There was a significant decrease in the K8+K14+ double positive cells for Zfp217 tumors treated with TCN-Pac compared to vector 
expressing tumors treated with Pac-TCN (p=0.03, by one-way ANOVA with Tukey’s multiple comparisons test).
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immunohistochemistry of proliferation markers (both Ki67 
and phospho-histone H3) and apoptosis markers (cleaved 
caspase 3). Levels of neither proliferation nor apoptosis 
were significantly different across the tumor cohorts, 
suggesting that there is no difference in proliferation or 
apoptosis within the tumor region (Figure 3A-3C) (one-
way ANOVA with Tukey’s multiple comparisons).
Zfp217 decreases tumor vasculature response
Since proliferation and apoptosis were not 
significantly different after treatment or overexpression 
of Zfp217, we next looked at changes in the microvessel 
density and maturity as factors that contribute to tumor 
burden and survival. We quantified the microvessel density 
after chemotherapy treatment by immunohistochemistry 
of CD31 (Figure 3D-3F). Interestingly, the tumors that 
overexpress Zfp217 contained significantly reduced 
numbers of blood vessels compared to tumors that 
overexpress vector (p=0.003, one-way ANOVA with 
Holm-Sidak’s multiple comparisons) (Figure 3E). 
Treatment with either TCN→PAC or PAC→TCN also 
decreased the microvessel density in both vector and 
Zfp217 overexpressing tumors, with particularly significant 
reduction in the Zfp217 overexpressing tumors. We also 
found a reduction in CD31 stained area in treated tumors, 
particularly in the TCN→PAC and PAC→TCN treated 
tumors that overexpress Zfp217, compared to vehicle 
(p=0.0096 and p=0.003, respectively, one-way ANOVA 
with Tukey’s multiple comparisons) (Figure 3F). However, 
the mean vessel size was not significantly different across 
cohorts (Supplementary Figure 2) (n.s., one-way ANOVA 
with Tukey’s multiple comparisons). These results suggest 
that both Zfp217 overexpression and combination therapy 
reduce microvessel number and area within the tumors.
To look at the nature of the vessels formed in tumors 
that overexpress Zfp217, we co-stained the tumors with 
the endothelial cell marker CD31 and the muscle and 
pericyte cell marker α-smooth muscle actin (SMA) (Figure 
3G). In the vehicle treated samples, the sparse vessels seen 
in the tumors that overexpressed Zfp217 were longer than 
the vessels of the vector control tumors (Figure 3H). The 
tumors with Zfp217 overexpression also had a higher 
percentage of CD31+SMA- vessels than seen in the vector 
control tumors (Figure 3I), suggesting the vessels in the 
Zfp217 tumors are either immature or leaky.
We next looked at the tumors treated with 
PAC→TCN and TCN→PAC. The samples from vector 
control tumors treated with either drug combination 
contained predominantly CD31+SMA+ vessels. The 
Zfp217 overexpressing tumors from treated animals 
(PAC→TCN or TCN→PAC) had increased numbers of 
CD31+SMA+ vessels, compared to Zfp217 overexpressing 
tumors treated with vehicle. In addition, PAC→TCN 
treatment tumors had shorter vessels compared to either 
the vehicle or TCN→PAC treatment tumors.
The vessels from the TCN→PAC treated animals 
had increased SMA coverage of vessels compared to 
vehicle control mice in both vector and Zfp217 expressing 
tumors. This suggests that TCN→PAC treatment leads to 
the maturation of the vessels in tumors that overexpress 
Zfp217.
Survival status of patient-derived tumor 
xenografts (PDX) suggests that treatment order 
matters with triciribine and paclitaxel
We used patient-derived tumor xenografts grown 
in immune compromised NOD SCID mice to determine 
the efficacy of TCN→PAC compared to PAC→TCN on 
tumors of human origin that also overexpress ZNF217 
(Figure 4A). The PDX tumors used were previously 
established and characterized for their gene expression 
levels [23]. The selected model (HCI-011) expressed the 
highest level of ZNF217 of all of the xenograft tumors 
tested. Indeed, ZNF217 was expressed at high levels in 
these tumors (Figure 4B).
Animals with PDX tumors were treated with 
single agent (PAC or TCN) or combination treatment 
(PAC→TCN or TCN→PAC) and a Kaplan-Meier survival 
analysis was completed (Figure 4C). The TCN→PAC 
animals had a median survival of 9 weeks compared to 5 
weeks for PAC→TCN treated animals (n.s. Kaplan-Meier 
with log-rank (Mantel-Cox) test). However, in contrast to 
the experiments in immune competent mice, the survival 
time of TCN→PAC treated mice was not significantly 
different from PAC treated mice.
We determined if immune cell recruitment 
contributed to the differences in survival after treatment 
seen between immune competent and immune 
compromised animals with tumors that overexpress Zfp217 
(same experiment as described in Figure 2). Quantification 
of CD45+ epithelial tumor cells showed no statistical 
difference between cohorts (n.s., one-way ANOVA with 
Tukey’s multiple comparisons) (Figure 5A-5B). These 
data suggest that lymphocyte recruitment is not the 
primary driver of the differences seen between the immune 
competent and immune compromised tumor cohorts.
DISCUSSION
In this study, we found that Zfp217 overexpression 
promotes chemoresistance associated with an increase in 
a progenitor cell population. Significantly, we identified 
a specific dosing regimen of triciribine followed by 
paclitaxel that can overcome the chemoresistance that 
results from Zfp217 overexpression. Interestingly, the 
observed increase in efficacy does not alter proliferation, 
apoptosis, or CD45+ immune cell recruitment, but we do 
observe changes in the vasculature. To our knowledge, this 
is the first report of a Zfp217-induced change in the tumor 
vasculature.
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Figure 3: Increased expression of Zfp217 decreases the microvessel density but does not affect proliferation or apoptosis 
rates. (A-C) Immunohistochemistry staining and quantification of paraffin embedded sections from vector and Zfp217 expressing tumor 
tissues. Tissue sections were stained using the ImmPACT DAB detection method and counterstained with hematoxylin. Slides were scanned 
using Aperio CT, and images were quantified using Aperio software for (A) Ki67, (B) phospho-histone H3, and (C) cleaved caspase-3. 
Each bar represents the mean ± SD and was analyzed by one-way ANOVA with Tukey’s multiple comparisons. (D) CD31+ IHC-stained 
vasculature. Images of IHC stained CD31 positive vessels with hematoxylin counterstained nuclei for each control or treated cohort that 
expresses either vector or Zfp217. Scale bar=100μm. (E) Microvessel density and (F) CD31+ stained tumor tissue. Scatter plots showing 
quantified data from Aperio validated microvessel quantification algorithm for (E) CD31+ microvessel density (one-way ANOVA with 
Holm-Sidak’s multiple comparisons) and (F) CD31+ stained regions (one-way ANOVA with Holm-Sidak’s multiple comparisons). Bars 
represent the mean for each cohort (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001). (G) CD31+SMA+ IF-stained vasculature. Images 
of tumor sections stained for CD31 and SMA treated with dual agents or vehicle for both vector and Zfp217 expressing tumors. Scale 
bar=200μm. (H) Quantification of size of vessels. Percentage of samples analyzed that had short (small), medium, and long (large) blood 
vessel size, referring to the vessel length. (I) Quantification of SMA coverage of CD31+ blood vessels. Percentage of samples analyzed that 
had low (<40% SMA+), medium (40-80% SMA+), or high (>80% SMA+) SMA coverage of CD31+ blood vessels.
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These data suggest that Zfp217 overexpression in the 
breast tumors promotes vasculature remodeling, marked by 
reduced numbers of vessels, increased vessel size, and an 
increased percentage of CD31+SMA- vessels compared to 
vector overexpression (Figure 5C-5D). Interestingly, after 
TCN→PAC treatment of the Zfp217 overexpressing tumors, 
not only does the overall survival of the cohort increase for 
the animals with Zfp217 overexpressing tumors, but also the 
tumor burden decreases while the vessels of these tumors 
revert to primarily CD31+SMA+ vessels. This suggests that 
the Zfp217 tumors respond to TCN→PAC treatment in part 
by vascular remodeling and by becoming CD31+SMA+. 
This vascular remodeling is consistent with either changes 
in pericyte coverage or the promotion of arteriogenesis 
and vasculture maturity and provides a rationale for the 
improvements seen in the animals treated with TCN→PAC.
The role of ZNF217 in promoting chemoresistance 
provided the rationale for revisiting the Akt inhibitor 
triciribine as a candidate for combination therapy in the 
clinical setting [2]. ZNF217 is required for and promotes 
increased activation of Akt, which also plays a critical role 
in promoting chemotherapy resistance in breast cancer 
cells [2, 5][24]. Several Akt inhibitors have been explored 
in various stages of clinical development as single agent or 
combination therapies [13]. Triciribine was the lead drug 
candidate identified from an in silico screen of ~50,000 
drugs specific for cancer cells that have high expression 
of ZNF217 [2].
In this study, we find that ZNF217 overexpression 
promotes resistance in vivo in response to combination 
therapies that include not only DNA damaging agents, 
such as doxorubicin, but also mitotic inhibitors, like 
the microtubule stabilizer epothilone B. Therefore, we 
cannot rule out contributions of ZNF217 overexpression 
to bypassing the G2/M checkpoint, which is the last 
opportunity for the cell to repair double strand DNA 
breaks and to prevent DNA damage from being carried 
into daughter cells. Damaged DNA present during G2/M 
Figure 4: Triciribine-paclitaxel (TCN→PAC) 
combination therapy has decreased efficacy in 
tumors from patient-derived tumor xenografts 
(PDX) grown in immunocompromised mice. (A) 
Experimental overview. The timeline depicts the strategy 
to perform orthotopic mammary transplants of (HCI-011) 
patient derived tumor xenograft tissues with high expression 
of ZNF217 using mice with the NOD-SCID background. 
Mice also received estrogen pellet implants as HCI-011 PDX 
tissue is estrogen responsive but not dependent. Mice received 
vehicle, single agent treatment of paclitaxel or triciribine 
or dual agent paclitaxel-triciribine or triciribine-paclitaxel. 
Tumor tissue was collected at death or at the terminal endpoint 
when diameter reached 2.5 cm. (B) ZNF217. Images of 
IHC stained with antibodies raised against ZNF217 show 
ZNF217+ cells with hematoxylin counterstained nuclei. Scale 
bar=100μm. (C) Kaplan-Meier survival curves. NOD-SCID 
mice bearing orthotopically grown HCI-011 PDX tissue, with 
high expression of ZNF217, received single or dual agent 
combination therapy. Kaplan-Meier survival curves show no 
change in median survival between cohorts.
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normally promotes mitotic catastrophe and cell death. 
Other studies have supported a role for ZNF217 in 
genomic instability and telomere length. First, ZNF217 
overexpression was found to immortalize human 
mammary epithelial cells (HMECs) through stabilized/
increased telomere length and increased telomerase 
activity [25]. ZNF217 overexpression also increased the 
numbers of mitotic cells and anaphase bridges, a marker 
of genomic instability, in cultured cells [26].
Resistance to paclitaxel, which stabilizes 
microtubules, could also be due to bypassing mitotic 
checkpoints, which is consistent with the anaphase 
Figure 5: Immunocompetent mice that overexpress Zfp217 were treated with triciribine-paclitaxel and have unaltered 
CD45+ immune cell number. (A) CD45. Images of IHC stained CD45+ cells with hematoxylin counterstained nuclei for each control 
or dual agent treated cohort. Scale bar=100μm. (B) Quantification of CD45+ cells. CD45+ cells were scored using Aperio software. Each 
bar represents the mean and analyses were conducted using One-way ANOVA with Tukey’s multiple comparisons. (C) Diagram describing 
results after vector overexpression + vehicle with legend. (D) Diagram describing results after ± Zfp217 overexpression + vehicle and 
after treatment (Paclitaxel→Triciribine, which are resistant to treatment, compared to Triciribine→Paclitaxel, which are responsive to 
treatment).
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bridges seen from the samples used in this study (data 
not shown) and the evidence of genomic instability that 
we and others have seen after ZNF217 overexpression 
[25–27]. Indeed, ZNF217 overexpression increases 
the expression of the mitotic kinase Aurora-A, which 
we previously found is regulated by ubiquitin-
dependent proteolysis and phosphorylation and leads 
to genomic instability and centrosome amplification 
[28, 29]. In addition, in cell culture an Aurora 
inhibitor had synergistic efficacy in combination with 
paclitaxel [6].
Tumors that overexpressed Zfp217 became 
resistant to combination chemotherapy treatment 
and had increased numbers of K8+K14+, while 
triciribine→paclitaxel (TCN→PAC) combination 
therapy led to a decrease in the K8+K14+ population in 
the tumors that also overexpressed Zfp217. This suggests 
that the TCN→PAC treatment reduces the number of 
cancer stem cells. The increase in K8+K14+ population is 
consistent with our findings that ZNF217 overexpression 
promotes an increase in a mammary stem/progenitor cell 
population [2]. ZNF217 has been identified as a target 
gene that is amplified in circulating cancer cells and is 
part of a signature that predicts response to therapy [30]. 
In addition, Zfp217 is a required factor for embryonic 
stem cell (ESC) self-renewal, pluripotency, and somatic 
cell reprogramming [31]. Zfp217 promotes epigenetic 
and epitranscriptomic changes that then activate the 
transcription of pluripotency genes and also regulates the 
N6-methyladenosine (m6A) RNA methylation within the 
cell [31].
Our study has implications for personalized 
therapies for patients with breast tumors that overexpress 
ZNF217. Based on our study, these patients are likely 
to respond to treatment with triciribine and paclitaxel 
combination therapy if treated in combination with a 
gapped schedule of triciribine treatment followed by 
paclitaxel treatment. Our study suggests that the treatment 
should be planned with the dose schedule and order in 
mind.
These pre-clinical data support results observed 
in breast cancer patients, namely that increased 
expression of ZNF217 imparts resistance to standard 
treatments used for breast cancer [2, 32, 33]. This study 
directly impacted the design of a Phase I-II clinical 
trial (NCT01697293) testing the efficacy of triciribine 
in combination with paclitaxel in patients with breast 
cancer and will impact a future Phase II clinical trial 
of poor prognosis ER+ metastatic breast cancer patients 
treated with triciribine. For these and future studies, 
increased expression of ZNF217 is an ideal prognostic 
biomarker for triciribine and endocrine therapy clinical 
trials.
ZNF217 is expressed at the highest levels in breast 
cancer patients with the worst prognosis. A detailed 
mechanistic analysis of the contribution of ZNF217 
to therapeutic resistance combined with pre-clinical 
modeling will inform the design of the best treatment plan 
to kill these cells, thereby reducing mortality in breast 
cancer patients with aggressive disease.
MATERIALS AND METHODS
Animals
Animal experiments were conducted in 
accordance with the University of Notre Dame 
Institution Animal Care and Use Committee guidelines 
(protocol # 15-10-2724). Mice used in this study were 
maintained under pathogen-free conditions in the 
University of Notre Dame Freimann Life Sciences 
animal facility. The immunocompetent mice used in 
these studies were maintained on FVB/n mice, and the 
immunocompromised mice were non-obese diabetic 
severely compromised immune deficient (NOD-SCID) 
[34]. The patient-derived tumor xenograft model (HCI-
011) [23] was used in accordance with IRB approval 
(protocol # 13-05-1062).
Tissue culture cell lines and culture conditions
The luciferase expressing murine breast tumor cell 
line, derived from a polyoma middle T mouse, Vo-PyMT-
Luc, was obtained from Conor Lynch [7] and maintained 
in DMEM-H21 media + 10% FBS. HEK293T cells were 
purchased from ATCC and maintained in DMEM-H21 
media + 10% FBS.
Plasmids and virus production
The lentiviral plasmid pEIT-Zfp217 and empty 
vector pEIT, containing the EF1α promoter and tomato 
fluorescent reporter, was used to generate lentiviral 
particles to transduce the PyMT cell line [35].
The EF1α promoter-driven tomato fluorescent 
lentiviral plasmids pEIT and pEIT-Zfp217 expressing a 
tomato fluorescent reporter gene were used to generate 
lentiviral particles. Virus was produced as described 
previously [36]. Briefly, for lentiviral packaging, 
HEK293T cells were plated in 10 cm tissue culture 
plates and transfected the following day. Two μg of the 
transducing vector pLVX, 1.5 μg of packaging vector 
pCMV-∆R8.2, and 0.5 μg of the VSV envelope vector 
pCMV-VSVG were co-transfected using calcium 
phosphate precipitation. The medium was changed the 
next day, and the cells were cultured for ~48 hours. 
Media containing lentiviral particles was collected and 
filtered through a 0.45 μm filter before storing at -80°C. 
The lentiviral particles were used at an MOI of 5 to 
transduce the PyMT-Luc cell line. Virus was titered and 
equal MOIs (MOI=5) of vector and ZNF217 virus were 
used to transduce the Vo-PyMT-Luc cells as described 
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previously [2]. After transduction and within one week 
of expression, the cells were sorted and collected using 
fluorescence activated cell sorting (FACS) to enrich for 
the cells expressing the tomato fluorescence protein. 
This generated the cell lines PyMT-pEIT and PyMT-
pEIT-Zfp217.
Tumor production in animal models
To establish syngeneic tumors, PyMT-pEIT and 
PyMT-pEIT-Zfp217 cells were injected (1x106 cells 
in 10 μl) orthotopically into the #4 mammary gland 
of FVB/n mice. For both experiments, tumors formed 
by two weeks post-transplant. Tumor measurements 
were made using electronic digital calipers, and tumor 
volumes were calculated using the modified tumor 
ellipsoid formula: Tumor volume =1/2(length x width2) 
[37, 38].
Generation of patient-derived xenografts was 
approved by the Institutional Review Board and has 
been described previously [23, 39]. At least six mice 
per treatment group were used. After tumors reached a 
minimum of 75 mm3 in size, treatment was initiatied. Mice 
were sacrificed when the tumor diameter reached 2.5 cm 
in length or width.
Therapeutics
For the experiment examining syngeneic 
tumors treated with EAC or vehicle, post-transplant 
mice were treated after three weeks with epothilone 
B (intravenous), adriamycin (intraperitoneal), and 
cyclophosphamide (intraperitoneal) (EAC) combination 
chemotherapy or DMSO. Nine mice were included in the 
vector DMSO cohort, seven mice were included in the 
Zfp217 DMSO cohort, and eight mice were inclued in 
both the vector and Zfp217 EAC chemotherapy treated 
cohorts. In another experiment with syngeneic tumors, 
beginning approximately 2 weeks post-transplant, 
mice received intraperitoneal injections of paclitaxel 
followed approximately 24 hours later by triciribine 
or the reciprocal dosing regimen. Similar to the Phase 
I-II clinical trial (NCT01697293), administration of 
triciribine was skipped every 3rd week of the treatment 
regimen. At least six mice per treatment group were 
used, and tumors were collected at death or when 
they reached 2.5 cm in diameter. For the experiment 
examining overall survival of a larger cohort of 
syngeneic tumors treated with EAC with a larger cohort, 
post-transplant mice were treated with EAC combination 
chemotherapy once the tumors were palpable. Tissues 
were collected once the tumors reached 2 cm in diameter. 
This experiment was completed twice, and the results 
were combined in Figure 1F with the indicated number 
of mice.
Mice were treated with the indicated drugs at the 
following concentrations: epothilone B diluted in DMSO 
(0.6 mg/kg) (LC Labs, Cat#: LC-E-5500), doxorubicin 
(Adriamycin) diluted in PBS (2 mg/kg) (Sigma-Aldrich, 
Cat#: D1515), cyclophosphamide diluted in PBS (120 mg/
kg) (Sigma-Aldrich, Cat#: C0768), paclitaxel diluted in 
DMSO (27 mg/kg) (LC Labs, Cat#: P-9600), and API-2 
(Triciribine) diluted in DMSO (12 mg/kg) (Tocris, Cat#: 
2151).
Tissue processing
Mammary and lung tissues were collected, fixed 
overnight in 4% paraformaldehyde, and transferred to 70% 
ethanol, processed and embedded in paraffin blocks prior 
to sectioning. Paraffin tissue blocks were sectioned at 4 
μm for IHC special stains.
Antibodies and immunostaining
The following antibodies were used for these 
studies: CD31 (Abcam 28364) 1:50, CD45 (BD 
Pharmingen 550539) 1:200, Cleaved caspase-3 
(CST9661) 1:200, Keratin-8 (Dev. Stud. Hybridoma 
Bank-Univ. of Iowa 531826) 1:50, Keratin-14 (Covance 
PRB-155P) 1:5000, Ki-67 (CST 12202) 1:400, Phospho-
Akt (CST 4051) 1:100. All immunohistochemical staining 
utilized sodium citrate heat-induced antigen retrieval and 
overnight incubation of primary antibody at 4°C, and 
mouse antibodies required use of the mouse on mouse kit 
(Vector Laboratories BMK-2202).
Image acquisition and analysis
Analysis of K8/K14: Fluorescence images 
were acquired on a Zeiss Axio Observer.Z1 inverted 
epifluorescence widefield microscope with the 
Apotome.2 structured illumination slider engaged. Imaris 
colocalization (x64 version 8.2.0; Imaris) was used to 
quantitatively assess colocalization of epithelial markers 
keratin-8 (green channel) and keratin-14 (red channel). 
Background subtraction was completed using range set to 
50 μm. After generating a colocalized image, cells with 
positive colocalization signal were manually annotated 
and data was reported as the number of K8+K14+ double 
positive cells per high power field. At least three high 
power fields were analyzed for each section of tissue 
analyzed.
Analysis of CD31/SMA: Images acquired on Zeiss 
Axio Observer.Z1 using (10X/0.30 M27) EC Plan-
Neufluar objective with 1.6X Optovar. Images were 
acquired using tiles function to capture a 52 image panel 
using the contour tool to draw a circular region within 
which the images were captured. The following filters 
(Ex, Em) and exposure times were used: 43 HE DsRed 
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(545, 572), 440 ms, 38 HE GFP (488, 509), 290 ms, 
and 49 DAPI (353, 465), 70 ms. The multi-image panel 
was created using Zeiss Zen pro 2012 software. The full 
mosaic tile image was opened, and representative areas 
were zoomed in at 50%.
Images overlayed with Imaris surfaces were 
acquired using a (40X/0.95 Korr M27) Plan-Apochromat 
objective with the Apotome.2 structured illumination 
slider engaged. The following filters (Ex, Em) and 
exposure times were used: 43 HE DsRed (545, 572), 35 
ms, 38 HE GFP (488, 509), 100 ms, and 49 DAPI (353, 
465), 12 ms.
Immunohistochemistry images were scanned by 
an Aperio CT scanner (Aperio Technologies) with a 20X 
objective. The generated digital images were saved on 
the eSlide Manager database (ver. 12.0.0.5027). Image 
analysis for Ki67, p-histone H3, and cleaved caspase-3 
was completed using the Aperio Nuclear algorithm with 
customized macro parameters set to score DAB and 
hematoxylin chromogen intensities. Image analysis for 
CD45 was completed using the Aperio Cytoplasmic 
algorithm with customized macro parameters set to 
score DAB and hematoxylin chromogen intensities. The 
raw data generated from the nuclear and cytoplasmic 
algorithms included percentage of positively stained 
cells, intensity of the stain, and area of analysis. Image 
analysis for CD31 was completed using the Aperio CD31 
microvessel algorithm with customized macro parameters 
set to score vessels based on detection of DAB chromogen 
intensity. The region joining and vessel completion 
parameters were set to 25 μm and 30 μm, respectively 
while the dark and light staining thresholds were set to 
105 and 165, respectively. The minimum vessel area 
threshold was set to 50 μm2 and the maximum vessel 
wall thickness was set to 4 μm. The raw data from the 
microvessel analysis included quantity of vessels, vessel 
density, vascular area, lumen area, and vessel perimeter. 
After running the customized macros, a markup image 
was generated and re-evaluated to confirm accuracy of 
the algorithms. The data generated was exported from 
ImageScope annotation files as an Excel spreadsheet 
and statistical analysis was completed using GraphPad 
Prism. Figure preparation was completed using the 
FIJI [40] plugin ScientiFig [41]. Vessel size and SMA 
coverage were determined manually and scored by two 
investigators.
Statistical analysis
Statistical analysis was completed using Prism 6 
software (GraphPad Software, Inc.). Unless otherwise 
stated, more than two cohorts were compared using 
ANOVA Kruskal-Wallis followed by Dunn’s multiple 
comparison tests. One exception is for calculating the 
microvessel density and CD31 stained regions (Figure 3E-
3F). In this case, we assumed Gaussian distribution due 
to the need to have vessels within a particular distance of 
cells, so we used the Holm-Sidak’s multiple comparison 
test.
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